CRISPR Therapeutics AGCRSP
What CRISPR Therapeutics AG does.
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.
We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo , CAR T approaches and regenerative medicine. Depending on the program, we take either an ex vivo approach, in which we edit cells outside of the human body before administering them to the patient, or an in vivo editing approach, where we deliver the CRISPR-based therapeutic directly to target cells within the human body.
• Hemoglobinopathies : Our most advanced program, CASGEVY, has received approval in the United States and other countries for the treatment of eligible patients with severe sickle cell disease, or SCD, or transfusion-dependent beta thalassemia, or TDT, two genetic disorders of hemoglobin, or hemoglobinopathies, with high unmet medical need. In addition, we have further research efforts, also in collaboration with Vertex, on targeted conditioning and in vivo editing of hematopoietic stem cells that have the potential to expand the number of patients that could benefit significantly.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $719,000 | $915.0M | $1.2M | $371.2M | $37.3M | $3.5M |
| Net income | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Free cash flow | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
More on CRSP.
- CRISPR Therapeutics AG summary
- CRISPR Therapeutics AG financial statements
- CRISPR Therapeutics AG key metrics
- CRISPR Therapeutics AG health scores and style box
- CRISPR Therapeutics AG earnings
- CRISPR Therapeutics AG dividends
- CRISPR Therapeutics AG valuation
- CRISPR Therapeutics AG ownership and insiders
- CRISPR Therapeutics AG peers
Figures from CRISPR Therapeutics AG's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.